1573-92-8Relevant articles and documents
-
Tucker,Whalley
, p. 632,634 (1949)
-
-
Andrew,H.F. et al.
, p. 755 - 759 (1972)
-
Practical synthesis of an open geodesic polyarene with a fullerene-type 6:6-double bond at the center: Diindeno[1,2,3,4-defg;l′,2′,3′,4′-mnop]chrysene
Bronstein, Hindy E.,Choi, Neil,Scott, Lawrence T.
, p. 8870 - 8875 (2002)
Diindeno[1,2,3,4-defg;l′,2′,3′,4′-mnop]chrysene (1), the smallest possible alkene-centered C60 substructure with a curved π-system, is obtained in 25-35% yield by flash vacuum pyrolysis of the twisted 1,1′-dibromobifluorenylidene (2) on a 100 mg scale at 1050 °C. At 1200 °C, the bowl-shaped hydrocarbon I rearranges to the planar isomer diindeno[5,6,7,1-defg;5′,6′,7′,1′-Imnop]chrysene (14) by a double 5/6 ring-expansion/ring-contraction. X-ray crystallography establishes that the central carbon atoms of 1 are nearly 80% as pyramidalized as the carbon atoms of C60 (POAV angles = 9.0° and 11.6° for 1 and C60, respectively). A four-step synthesis has been developed to prepare the pyrolysis precursor (2) as a mixture of (E)- and (Z)-isomers in 39% overall yield from commercially available 9-fluorenone-l-carboxylic acid (10).
Synthesis and biological evaluation of 9-fluorenone derivatives for SPECT imaging of α7-nicotinic acetylcholine receptor
Gao, Hang,Wang, Shuxia,Qi, Yueheng,He, Guoxue,Qiang, Bingchao,Wang, Sixuan,Zhang, Huabei
, (2019)
The α7-nicotinic acetylcholine receptor (α7-nAChR) subtype, is found to have a connection with the pathogenesis of a variety of psychiatric and neurological disorders. Herein, we report the development of radioiodinated 9-fluorenone derivatives as single-photon emission computed tomography (SPECT) imaging tracers for α7-nAChRs. Among the derivatives, the best member of the series 10 (Ki = 2.23 nM) were radiolabeled with 125I for in vitro and in vivo studies. The radiotracer [125I]10 exhibited robust brain uptake and specifically labeled α7-nAChRs with a peak uptake value of 9.49 ± 0.87%ID/g in brain. Blocking studies demonstrated that the tracer was highly specific toward α7-nAChR. Furthermore, ex vivo autoradiography and micro-SPECT/CT dynamic imaging in mice confirmed the excellent imaging properties. In addition, molecular docking was also performed to rationalize the potency of the chosen compounds towards α7-nAChRs. To conclude, compound 10 could serve as a promising radiotracer for the α7-nAChRs.
Synthesis of novel metal (II) complexes tailored from 9-oxo-9H-fluorene-1-carboxylic acid via green protocol: DNA cleavage and anticancer studies
Kumbar, Mahantesh,Patil, Sangamesh A.,Toragalmath, Shivakumar S.,Jawoor, Shailaja S.,Shettar, Arun
, (2019/11/11)
Despite being a polycyclic aromatic compound, fluorenone is not classified as carcinogenic. Some of the derivatives of fluorenone and metal complexes embedded with fluorenone based ligands exhibited challenging biological activities, including anticancer activity. The current investigation hence focuses on synthesis, characterization and anticancer activities of fluorenone based ligands and their coordinate compounds of some first row transition metals. The stoichiometry of all the synthesized metal complexes is found to be 1: 2 (metal: ligand) with the general formula [M(L)2], L = singly deprotonated ligand, whereas the geometry of all the metal complexes is found to be octahedral. The synthesized ligands and their respective metal (II) complexes were found to cleave the pBR322 DNA, during gel electrophoresis studies. The inhibition of cancer cell growth has been confirmed by fluorescence imaging techniques using DAPI as staining dye. The IC50 values of ligands and their metal (II) complexes suggest that synthesized compounds are more active towards A549 (human lung adenocarcinoma) cell line when compared with the standard drug Paclitaxel. In case of MCF-7 (human breast carcinoma) cell line, compound Cu(L2)2 is found to be more active than the standard drug Paclitaxel.
Fluorenone ligand compounds of alpha7 nicotine acetylcholine receptor and application of compounds
-
Paragraph 0056-0060, (2019/08/12)
Embodiments of the invention provide fluorenone ligand compounds of an alpha7 nicotinic acetylcholine receptor. The compounds are represented by a formula (I) shown in the description, wherein X is a6-10 membered nitrogen-containing heterocyclic group, and the nitrogen-containing heterocyclic group is unsubstituted or substituted by C1-C4 alkyl; R1 is one selected from the group consisting of amino, nitro, halogen and halogen radioisotopes, and R2 is hydrogen, or the R1 is hydrogen and the R2 is one selected from the group consisting of the amino, the nitro, the halogen or the halogen radioisotopes; and when the X is a group represented in the description, the R1 and the R2 are not selected from the amino, fluorine and fluorine radioisotopes. The ligand compounds provided by the inventionhave higher affinity with the alpha7 nicotinic acetylcholine receptor, and are excellent ligand compounds of the alpha7 nicotinic acetylcholine receptor; and further, the ligand compounds of the alpha7 nicotinic acetylcholine receptor can be used as a PET imaging agent or a single-photon emission computed tomography (SPECT) imaging agent after being radiochemically labeled.
